Trials / Completed
CompletedNCT04758234
A Study of LY3549492 in Healthy Participants
A Randomized, Double-Blind, Single-Ascending Dose and Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in healthy participants. The blood tests will be performed to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study includes two parts and will last up to approximately 76 days for each participant, including screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3549492 | Administered orally. |
| DRUG | Placebo | Administered orally. |
Timeline
- Start date
- 2021-02-22
- Primary completion
- 2022-01-10
- Completion
- 2022-01-10
- First posted
- 2021-02-17
- Last updated
- 2022-02-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04758234. Inclusion in this directory is not an endorsement.